Synapse
⌘+K
Synapse
PulseExploreClubsResearchersJournals
Instagram
HomeClubsExplore
December 8, 2025BloodOpen Access

Efficacy, safety, and NGS analysis of orelabrutinib combined with obinutuzumab in untreated marginal zone lymphoma

View Full Paper
Ask AI
Bookmark
Share

Authors

SZShujuan ZhouYSYifen ShiSJSongfu Jiang

Discussion

Loading...

Member takes

Overview

Phase II trial shows 100% overall response rate in untreated marginal zone lymphoma patients, suggesting effective treatment combining BTK inhibitors and anti-CD20 antibodies.

Key Points

  • Orelabrutinib and obinutuzumab combination achieved 100% overall response in nine evaluable patients with marginal zone lymphoma.
  • Progression-free survival and overall survival rates were both 100% at 12 months, indicating strong efficacy of the treatment.
  • Adverse events reported included thrombocytopenia and mild cutaneous bleeding, demonstrating manageable toxicity.
  • NGS analysis revealed mutations affecting NOTCH signaling and antigen processing, which may guide future therapies.

Cite This Study

Zhou et al. (2025) studied this question.

synapsesocial.com/papers/69362f484fa91c937236d71fhttps://doi.org/10.1182/blood-2025-7121
View Full Paper
Ask AI
Bookmark
Share

Also Consider

Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context:

  1. 1Preliminary analysis of orelabrutinib combined with obinutuzumab in the treatment of marginal zone lymphoma (Orion Study)2025
  2. 2Orelabrutinib combined with bendamustine-rituximab or obinutuzumab followed by orelabrutinib maintenance in untreated marginal zone lymphoma (Optimize): A multicenter, single-arm, phase II study2025 · 1 citations
  3. 3Preliminary study results of orelabrutinib in combination with rituximab for treatment-Naïve marginal zone lymphoma: A prospective single-arm clinical trial2025 · 1 citations
  4. 4Efficacy and safety of first-line orelabrutinib combined with obinutuzumab (With or Without Bendamustine) in high-risk marginal zone lymphoma: Results from the orchid study2025
  5. 5Real-world efficacy and safety of orelabrutinib-based regimens in the treatment of marginal zone lymphoma2025